You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,410,957


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,410,957
Title:Method of treatment using bisphosphonic acid
Abstract:The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Inventor(s): Bauss; Frieder (Neuhofen, DE), Pichler; Bernhard (Ketsch, DE), Turley; Stephen (Bottmingen, CH)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:10/430,007
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,410,957
Patent Claims: 1. A method for treating osteoporosis comprising commencing treatment by orally administering to a subject in need of such treatment, on a single day, a first dose in the form of a tablet, wherein said tablet comprises an amount of a pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid and continuing said treatment by orally administering, once monthly on a single day, a tablet comprising an amount of a pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid.

2. The method of claim 1, wherein the pharmaceutically acceptable salt is a sodium salt of ibandronic acid.

3. The method of claim 2 wherein the pharmaceutically acceptable salt is a monosodium, disodium, or trisodium salt of ibandronic acid.

4. The method of claim 3 wherein the pharmaceutically acceptable salt is a monosodium salt of ibandronic acid.

5. The method of claim 4 wherein the pharmaceutically acceptable monosodium salt of ibandronic acid is a monohydrate.

6. A method for treating osteoporosis consisting of orally administering to a subject in need of such treatment, once monthly on a single day, a tablet comprising an amount of a pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid.

7. The method of claim 6, wherein the pharmaceutically acceptable salt is a sodium salt of ibandronic acid.

8. The method of claim 7 wherein the pharmaceutically acceptable salt is a monosodium, disodium, or trisodium salt of ibandronic acid.

9. The method of claim 8 wherein the pharmaceutically acceptable salt is a monosodium salt of ibandronic acid.

10. The method of claim 9 wherein the pharmaceutically acceptable monosodium salt of ibandronic acid is a monohydrate.

11. The method of claim 2 wherein the tablet comprises at least one member selected from the group consisting of lactose, maize starch, talc, stearic acid, a salt of stearic acid, polyvinylpyrrolidone, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, silicon dioxide, hydroxypropyl methyl cellulose, titanium dioxide, and polyethylene glycol 6000.

12. The method of claim 2 wherein the tablet comprises stearic acid.

13. The method of claim 2 wherein the tablet comprises a salt of stearic acid.

14. The method of claim 2 wherein the tablet comprises silicon dioxide.

15. The method of claim 2 wherein the tablet comprises cross-linked polyvinylpyrrolidone.

16. The method of claim 7 wherein the tablet comprises at least one member selected from the group consisting of lactose, maize starch, talc, stearic acid, a salt of stearic acid, polyvinylpyrrolidone, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, silicon dioxide, hydroxypropyl methyl cellulose, titanium dioxide, and polyethylene glycol 6000.

17. The method of claim 7 wherein the tablet comprises stearic acid.

18. The method of claim 7 wherein the tablet comprises a salt of stearic acid.

19. The method of claim 7 wherein the tablet comprises silicon dioxide.

20. The method of claim 7 wherein the tablet comprises cross-linked polyvinylpyrrolidone.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.